Latest Conference Articles

Patients with BRCA-, ATM- and CDK12-mutated mCRPC treated with frontline olaparib plus abiraterone acetate experienced delays in disease progression and improved outcomes.

Subsequent therapies in patients with metastatic hormone-sensitive prostate cancer who were censored from primary overall survival follow-up from the ARASENS trial, according to a post hoc sensitivity analysis, confirmed the overall survival benefit derived from darolutamide plus androgen deprivation therapy and docetaxel.

Favorable ECOG performance status and less advanced disease may predict which patients with metastatic colorectal cancer might have long-term remission when treated with regorafenib.

After radical prostatectomy, patients with prostate cancer treated with abiraterone acetate plus prednisone and apalutamide had improved outcomes without a significant impact on their health-related quality of life.

First-line treatment with nivolumab plus ipilimumab for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer can be considered a standard-of-care option based on results from the phase 3 CheckMate-8HW trial.

Treatment with belzutifan for advanced/metastatic clear cell renal cell carcinoma delayed worsening symptoms and improved quality of life.

Researchers did not observe any grade 3 or 4 adverse events with darolutamide with androgen deprivation therapy for 6 months followed by radical prostatectomy in patients with locally advanced prostate cancer.

All patients enrolled in the EV-302 trial with previously untreated, locally advanced, or metastatic urothelial carcinoma obtained a survival benefit with enfortumab vedotin-ejfv plus pembrolizumab.

Cabozantinib plus atezolizumab may be a new treatment option for patients with metastatic castration-resistant prostate cancer whose disease progressed on novel hormonal therapy.

Patients with high-risk prostate cancer treated with a higher dose of radiation therapy and long-term androgen deprivation therapy improved progression-free, cancer-specific, and overall survival compared with the standard dose of radiation.

Frontline olaparib plus abiraterone/prednisone improved progression-free survival and responses in patients with metastatic castration-resistant prostate cancer compared with each of the components of the therapy alone.

Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.

Despite germline and somatic testing being the standard of care for patients with metastatic castration-resistant prostate cancer, rates of its real-world use shows that it may be underutilized, which may negatively impact therapeutic offerings.

Darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer may lower hospitalization rates but marginally longer lengths of stay vs treatment with placebo, androgen deprivation therapy, and docetaxel.

Fruquintinib showed potential in providing an improved quality of life and survival benefit in patients with previously treated metastatic colorectal cancer.

Disitamab vedotin either alone or with TKIs, ICIs, or other antiangiogenic agents were consistently effective in patients with HER2-positive or -low breast cancers.

Detecting minimal residual disease with ctDNA in patients with stage II/III colorectal cancer may strongly predict disease recurrence and the potential benefit from adjuvant chemotherapy.

Treatment with durvalumab, bevacizumab, and TACE improved PFS in embolization-eligible patients with unresectable hepatocellular carcinoma.

Treatment with regorafenib in patients with unresectable hepatocellular carcinoma and poor liver function may lead to serious side effects that may result in discontinuation of the treatment.

Neoadjuvant treatment with camrelizumab plus nab-paclitaxel and cisplatin improved pathologic complete responses compared with chemotherapy alone in patients with esophageal squamous cell carcinoma.

Patients with advanced hepatocellular carcinoma treated with frontline pembrolizumab plus lenvatinib showed a 3-year or more response among 35% of responders, although additional efficacy results from the trial are consistent with previous findings from the phase 3 LEAP-002 trial.

Patients with esophageal squamous cell carcinoma obtained significant survival improvements when treated with tiragolumab plus atezolizumab and chemotherapy compared with chemotherapy alone.

Patients with resectable gastric and GEJ cancers, regardless of region, experienced an improved pathologic complete response to treatment with durvalumab plus neoadjuvant FLOT compared with chemotherapy alone.

Overall survival and progression-free survival improves with nivolumab plus chemotherapy compared with chemotherapy alone in the overall population and in patients with a PD-L1 CPS of 5 or greater.

Nivolumab plus chemotherapy enhanced overall survival and progression-free survival in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

Treatment with pegylated liposomal doxorubicin and cyclophosphamide in the neoadjuvant setting, followed by a taxane, in addition to trastuzumab and pertuzumab, resulted in antitumor activity in patients with HER2-positive breast cancer.

After 3 years, ruxolitinib provided improved control for steroid refractory or dependent chronic graft-versus-host disease when compared with best available treatment.

Reducing the dose of talquetamab, a GPRC5D/CD3 bispecific antibody, may improve side effect rates while maintain high response rates in patients with relapsed or refractory multiple myeloma.